Skip Nav Destination
Issues
15 April 2008
-
Cover Image
Cover Image
CXCL5 expression (red) in the rat colon cancer cell line CC531S (nuclei, green). Low level of CXCL5 expression is associated with aggressive tumor growth in a rat model and predicts decreased survival rates in patients treated with surgery for colorectal cancer. A positive correlation between levels of CXCL5 and intratumoral CD8+ T-cell infiltration in colon cancer suggests that CXCL5 is involved in themigration of immune cells into the tumor and might be implicated in the antitumor immune response. For further details, please see Speetjens and coworkers on page 2276 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Molecular Pathways
Human Cancer Biology
Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model
Urszula Dougherty; Amikar Sehdev; Sonia Cerda; Reba Mustafi; Nathaniel Little; Weihua Yuan; Sujatha Jagadeeswaran; Anusara Chumsangsri; Jorge Delgado; Maria Tretiakova; Loren Joseph; John Hart; Ezra E.W. Cohen; Lata Aluri; Alessandro Fichera; Marc Bissonnette
Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients
Frank M. Speetjens; Peter J.K. Kuppen; Maro H. Sandel; Anand G. Menon; Danny Burg; Cornelis J.H. van de Velde; Rob A.E.M. Tollenaar; Hans J.G.M. de Bont; J. Fred Nagelkerke
KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors
Séverine Tabone-Eglinger; Frédéric Subra; Hiba El Sayadi; Laurent Alberti; Eric Tabone; Jean-Philippe Michot; Nathalie Théou-Anton; Antoinette Lemoine; Jean-Yves Blay; Jean-François Emile
Imaging, Diagnosis, Prognosis
Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
Kazuhiko Ino; Eiko Yamamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Norio Yoshida; Mikio Terauchi; Akihiro Nawa; Tetsuro Nagasaka; Osamu Takikawa; Fumitaka Kikkawa
The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma
Robert Brown; Magdalena Zlatescu; Angelique Sijben; Gloria Roldan; Jay Easaw; Peter Forsyth; Ian Parney; Robert Sevick; Elizabeth Yan; Douglas Demetrick; David Schiff; Gregory Cairncross; Ross Mitchell
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Noopur Raje; Sook-Bin Woo; Karen Hande; Jeffrey T. Yap; Paul G. Richardson; Sonia Vallet; Nathaniel Treister; Teru Hideshima; Niall Sheehy; Shweta Chhetri; Brendan Connell; Wanling Xie; Yu-Tzu Tai; Agnieszka Szot-Barnes; Mei Tian; Robert L. Schlossman; Edie Weller; Nikhil C. Munshi; Annick D. Van Den Abbeele; Kenneth C. Anderson
Cancer Therapy: Clinical
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
Rebecca B. Klisovic; Wendy Stock; Spero Cataland; Marko I. Klisovic; Shujun Liu; William Blum; Margaret Green; Olatoyosi Odenike; Lucy Godley; Jennifer Vanden Burgt; Emily Van Laar; Michael Cullen; A. Robert Macleod; Jeffrey M. Besterman; Gregory K. Reid; John C. Byrd; Guido Marcucci
Cancer Therapy: Preclinical
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Torsten Trowe; Sotiria Boukouvala; Keith Calkins; Richard E. Cutler, Jr.; Ryan Fong; Roel Funke; Steven B. Gendreau; Yong D. Kim; Nicole Miller; John R. Woolfrey; Valentina Vysotskaia; Jing Ping Yang; Mary E. Gerritsen; David J. Matthews; Peter Lamb; Timothy S. Heuer
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.